Skip to main
ATAI

ATAI Stock Forecast & Price Target

ATAI Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 0%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

AtaiBeckley is a clinical-stage biopharmaceutical company with a promising pipeline of therapies for treating mental health disorders. The recent deal with Eli Lilly, with a total value of approximately $2.8 billion, further validates the potential of these therapies and highlights the attractiveness of the TRD market. With a lowered probability of success for BPL-003 and VLS-01 due to updated clinical data, AtaiBeckley's valuation and potential peak revenues have been revised, but the current premium of ~40% over the last one-month average price suggests the market has confidence in the company's future success.

Bears say

AtaiBeckley is currently experiencing upside risks due to potential acquisition interest in the company, a positive Phase 2b topline readout for VLS-01 triggering a milestone payment, and expedited FDA approval for their therapies. However, there are concerns about the sustainability of the company's treatment model in terms of providing adequate clinical depth and durability while still maintaining operational convenience and cost-effectiveness. Additionally, the potential for additional bidders to enter the market could drive up the acquisition price, making it an uncertain investment opportunity.

ATAI has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 0% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atai Life Sciences BV (ATAI) Forecast

Analysts have given ATAI a Buy based on their latest research and market trends.

According to 7 analysts, ATAI has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atai Life Sciences BV (ATAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.